论文部分内容阅读
35例磺脲类药物继发性失效的2型糖尿患者接受为期12周的诺和锐30联合二甲双胍治疗,给予早餐前和晚餐前立刻注射,观察治疗前后的空腹血糖(FPG)、餐后2小时血糖(2hPG)、糖化血红蛋白(HbA1c)、空腹C肽、餐后2小时C肽、体重指数。结果:患者的FPG、2hPG、HbA1c均较治疗前明显下降(P<0.01),餐后2小时C肽浓度亦均较治疗前明显升高(P<0.01)。结论:诺和锐30联合二甲双胍能够有效控制空腹及餐后血糖,改善胰岛B细胞功能,减少低血糖的危险性。
Thirty-five patients with type 2 diabetes mellitus secondary to sulfonylurea were treated with Novo-Rui 30 plus metformin for 12 weeks. Immediate pre-breakfast and evening-time pre-meal injections were given. The fasting plasma glucose (FPG) Hourly blood glucose (2hPG), glycosylated hemoglobin (HbA1c), fasting C-peptide, 2-hour postprandial C-peptide, body mass index. Results: The FPG, 2hPG and HbA1c in patients were significantly lower than those before treatment (P <0.01). The C peptide concentrations at 2 hours after meal were significantly higher than those before treatment (P <0.01). Conclusion: Novo-Rui 30 combined with metformin can effectively control fasting and postprandial blood glucose, improve islet B cell function and reduce the risk of hypoglycemia.